by According to Precedence Research, during the forecast period of 2022 to 2030, the global virtual clinical trials market is estimated to develop at a compound annual growth rate (CAGR) of 5.27%. The global virtual clinical trials market was valued at USD 8.95 billion in 2021, and it is predicted to exceed USD 14.2 billion by 2030. The study investigates several elements and their consequences on the growth of the virtual clinical trials market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1850
This report focuses on virtual clinical trials market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall virtual clinical trials market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
Report Scope of the Virtual Clinical Trials Market
| Report Coverage | Details |
| Market Size by 2030 | USD 14.2 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 5.27% |
| North America Market Share in 2021 | 50% |
| Interventional Configuration Segment Market Share in 2021 | 47% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Study Design, Indication, Phase, Geography |
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of virtual clinical trials, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of virtual clinical trials has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the virtual clinical trials market.
Some of the prominent players in the virtual clinical trials market include:
- ICON, plc
- Parexel International Corporation
- IQVIA
- Covance
- PRA Health Sciences
- LEO Innovation Lab
- Medidata
- Oracle
- CRF Health
- Clinical Ink
- Medable, Inc.
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1850
Segments Covered in the Report
By Study Design
- Interventional
- Observational
- Expanded Access
By Indication
- Oncology
- Cardiovascular
- CNS
- Autoimmune/Inflammation
- Metabolic/Endocrinology
- Infectious Disease
- Genitourinary
- Ophthalmology
- Others
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Virtual Clinical Trials Market
5.1. COVID-19 Landscape: Virtual Clinical Trials Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Virtual Clinical Trials Market, By Study Design
8.1. Virtual Clinical Trials Market, by Study Design, 2022-2030
8.1.1 Interventional
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Observational
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Expanded Access
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Virtual Clinical Trials Market, By Indication
9.1. Virtual Clinical Trials Market, by Indication, 2022-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Cardiovascular
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. CNS
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Autoimmune/Inflammation
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Metabolic/Endocrinology
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Infectious Disease
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Genitourinary
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Ophthalmology
9.1.8.1. Market Revenue and Forecast (2017-2030)
9.1.9. Others
9.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Virtual Clinical Trials Market, By Phase
10.1. Virtual Clinical Trials Market, by Phase, 2022-2030
10.1.1. Phase I
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Phase II
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Phase III
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Phase IV
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Virtual Clinical Trials Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.1.2. Market Revenue and Forecast, by Indication (2017-2030)
11.1.3. Market Revenue and Forecast, by Phase (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Phase (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Phase (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.2.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.3. Market Revenue and Forecast, by Phase (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Phase (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Phase (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Phase (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Phase (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.3.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.3. Market Revenue and Forecast, by Phase (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Phase (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Phase (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Phase (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Phase (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.3. Market Revenue and Forecast, by Phase (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Phase (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Phase (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Phase (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Phase (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.5.3. Market Revenue and Forecast, by Phase (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Phase (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Study Design (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Phase (2017-2030)
Chapter 12. Company Profiles
12.1. ICON, plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Parexel International Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. IQVIA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Covance
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. PRA Health Sciences
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. LEO Innovation Lab
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medidata
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Oracle
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. CRF Health
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Clinical Ink
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1850
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
